EmendoBio

EmendoBio, founded in 2015, is a pioneering entity in the realm of Biotechnology with its headquarters in the United States. The company operates at the forefront of the Health Care, Health and Wellness, and Pharmaceutical industries. Under the compelling slogan, "Making any gene targetable," the company aims to redefine gene therapy through its advanced gene editing tools.

Addressing key technological gaps in treating genetic disorders, EmendoBio applies its proprietary expertise in protein engineering. By advancing innovative and disruptive protein tools, the firm seeks to overcome the prevalent bottlenecks within the gene therapy field. Despite its promising mission, the company has not disclosed its last investment details or investor engagements to date.

For investors, EmendoBio represents a strategic interest in the convergence of cutting-edge biotechnology and health care, offering potential leverage in the evolving landscape of personalized medicine.